Pilot Study to Evaluate the Safety and Effectiveness of the CereVasc eShunt™ System in the Treatment of Communicating Hydrocephalus

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The eShunt™ System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age \> 18

• Subject provides Informed Consent (IC)

• Post-aneurysmal SAH with Hunt and Hess Grades I-IV with EVD in place with the need for a permanent CSF shunt determined through a failed EVD clamping trial defined as:

‣ Post-clamping ICP of \> 20 cmH2O for 15 min, or

⁃ Post-clamping ICP \> 25 cmH2O for \< 15 min with patient intolerance to EVD clamping

⁃ Post-clamping ICP \>15 cmH2O for 15 min with radiographic evidence of ventriculomegaly

• Clinical signs and symptoms of communicating hydrocephalus

• Neurologically stable without evidence of severe vasospasm

• Pre-procedure MRI with gadolinium confirmation of IPS (inferior petrosal sinus) and CPA (cerebellopontine angle) cistern anatomy suitable for eShunt Implant deployment as confirmed by SSC (subject screening committee)

• Pre-procedure CT confirmation of no obstruction preventing CPA cistern access at target implant site (e.g., petrous bone) as confirmed by SSC

Locations
Other Locations
Argentina
Clínica La Sagrada Familia
RECRUITING
Buenos Aires
Contact Information
Primary
Ona Whelove
clinicaltrials@cerevasc.com
4155152885
Backup
DJ Cass
clinicaltrials@cerevasc.com
Time Frame
Start Date: 2020-10-01
Estimated Completion Date: 2027-12-01
Participants
Target number of participants: 30
Treatments
Experimental: Treatment Arm
The Treatment Arm receives the eShunt implant
Related Therapeutic Areas
Sponsors
Collaborators: Bioscience Consulting, Inc., Simplified Clinical Data Systems, LLC, AlvaMed, Inc.
Leads: CereVasc Inc

This content was sourced from clinicaltrials.gov